Replies to post #390645 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

http://www.ipharminc.com/press-release/2019/1/2/innovation-pharmaceuticals-receives-new-brilacidin-patent-further-expanding-intellectual-property-estate#:~:text=The%20%E2%80%9CIssue%20Notification%E2%80%9D%20of%20the%20patent%20%28Projected%20U.S.,The%20pharmaceutical%20composition%20can%20also%20contain%20Tris-buffered%20saline.

[frenchbroad]

You use information from 2014??
"IPIX is facing a patent cliff for brilacidin. Based upon IPIX’s own information, the “useful life” of the brilacidin patent ends by 2028. IPIX has been giving us this information for years (see 10K for the period ended 6/30/14 that includes brilacidin [10K from 6/30/14]). "

New patents have been filed in 8 years and older patents have been updated.

Oral Mucositis
"The European patent supplements other Brilacidin-OM patents that have been granted in the United States, Asia (Japan, Taiwan, China), Oceania (Australia) and South Africa.
All currently issued patents have an expiration date of 2032."
https://www.biospace.com/article/releases/innovation-pharmaceuticals-granted-european-patent-for-brilacidin-in-the-prevention-of-oral-mucositis/

Gastrointestinal Inflammation
"Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases of the Gastrointestinal Tract
Pending – United States, Patent Cooperation Treaty (PCT) – National phase entered in Australia.Europe and Japan– Granted
Treatment Of Inflammatory Diseases of the Gastrointestinal Tract
Patents Expire: 2036"

Anti-Bacterial
":Cyclic Compounds And Methods Of Making And Using The Same
United States: issued 10/18/16
Patent Expires: 2032
Cyclic compounds, compositions, methods of inhibiting the growth of a bacteria, and method of treating a mammal having a bacterial infection"

Anti-Viral
"In 2021, the Company filed a non-provisional patent application with the U.S. Patent and Trademark Office in support of Brilacidin’s use as an antiviral treatment including the SARS-CoV-2 virus.
"https://www.sec.gov/Archives/edgar/data/1355250/000147793221006717/ipix_10k.htm

MRSA and Antibiotic Resistance
"Receiving QIDP designation means that Brilacidin is now eligible for additional FDA incentives in the approval and marketing path, including Fast Track designation and Priority Review for development and a five-year extension of market exclusivity."
https://www.biospace.com/article/releases/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda-/